Amarin Corp Plc (AMRN)

[FlyFishingStocks]

Interesting. Guess who produced Tamiflu? The same company that developed Remdesivir; Gilead Sciences. How does Vascepa’s efficacy compare?
Tamiflu:

Prevention:

The results of several clinical studies show that Tamiflu is up to 92% effective in preventing influenza illness in adolescents, adults and the elderly when taken once daily. The studies examined Tamiflu’s ability to prevent the development of flu in three different settings: households, communities and residential nursing homes. The results can vary year-to-year depending on the incidence of flu

.tamiflu-granted-fda-approval-for-the-prevention-of-influenza

Treatment:

Compared with placebo, both standard-dose and high-dose oseltamivir reduced the mean illness duration from 103 to 70 hours and reduced symptom severity by 40%.

what-is-the-efficacy-of-oseltamivir-in-the-treatment-of-influenza

Vascepa in comparison:

Prevention:
To be determined by results of the next Vascepa-COVID-19 prevention trial( PREPARE-IT) results (1/21/2021)

Treatment:
Vascepa arm reduced the FLU-Pro score by 54% COVID-19 patients.

Remdesivir:

Treatment:

In the randomized, double-blind, placebo-controlled ACTT-1 trial, Veklury significantly improved time to recovery as compared to placebo – by five days in the overall study population (10 vs. 15 days;
The odds of improvement in clinical status with the 10-day treatment course of Veklury versus standard of care were also favorable, trending toward but not reaching statistical significance (odds ratio 1.31; 95% CI, 0.88 to 1.95).
n parallel with the FDA approval of Veklury, the FDA also issued a new Emergency Use Authorization (EUA) for the use of Veklury to treat hospitalized pediatric patients under 12 years of age weighing at least 3.5 kg or hospitalized pediatric patients weighing 3.5 kg to less than 40 kg with suspected or laboratory confirmed COVID-19 for whom use of an intravenous (IV) agent is clinically appropriate. This authorization is temporary and may be revoked, and does not take the place of the formal submission, review and approval process for the use of Veklury in this patient population.

us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid19


We don’t have direct similar evidence, but it seems based on the vastly improved FLU-PRO score that Vascepa would challenge the efficacy (33% shortened recovery time) of Remdesivir.


Vascepa is evolving into a beautiful equation:

REDUCE-IT + EVAPORATE + Cardiolink-9(The primary biomarker endpoint of the study was within-group changes in high-sensitivity C-reactive protein (hsCRP), a measure of inflammation. Within-group changes in D-dimer were also examined. VASCEPA administration resulted in a 25% reduction in hsCRP (p=0.011) as well as a reduction in D-dimer (p=0.048))
=
Successful(significant), efficacious outcomes of ongoing trials: CRC recurrence, Breast Cancer, Alzheimer’s, NASH, etc.

The label is about to expand and we are about to become GILD shareholders.